Founder Secondary Sales: Taking Liquidity Without Breaking QSBS

A Bay Area founder who takes a $10M tender offer at year four instead of waiting for year five can hand $2M+ of avoidable federal tax to the IRS in a single signature. If you founded a Series C company in 2021 in San Jose, Palo Alto, or Mountain View, you are probably four or five years into a pile of founder stock that is worth a lot more on paper than in your bank account. Your lead investor is hinting at a tender offer alongside the next round. A growth fund has approached you directly about buying a slice of your common stock through an SPV. Your spouse has started using the phrase "house in Los Altos" in casual conversation.

This is the founder secondary sale moment. Done right, it converts illiquid common into real cash while preserving the federal tax shelter on the rest of your stake. Done wrong, it triggers ordinary income, blows up your Section 1202 QSBS exclusion on the shares you sold, violates a lockup, or starts a clock you did not realize was running.

This guide walks through the four common structures, the tax mechanics of each, the QSBS preservation rules, the §1045 rollover safety valve, the §83(b) interaction for unvested stock, and a full worked example with both federal and California numbers. We run these analyses regularly with founders through our startup founder practice at Silicon Valley Tax.

What a Secondary Sale Actually Is

In startup land, a secondary sale is any sale of existing shares from one shareholder to a third party. The company is not the seller and does not receive the proceeds. That is the entire definition, and it is also the entire QSBS problem in a nutshell.

Compare to a primary issuance: the company creates new shares, sells them directly to investors in a financing round, and pockets the cash to fund operations. Primary issuance is what creates QSBS for the buyer, because the buyer acquired the stock at original issuance from the corporation, which is one of the five core tests under IRC §1202(c)(1).

Secondary sales come in four common flavors:

• Company-run tender offer. The company organizes a structured event where one or more investors (usually the lead in a concurrent primary round) offer to buy a fixed dollar amount of common stock from existing holders at a set price. Eligibility, caps, and pricing are uniform across participating shareholders. Most modern Series C and later rounds include one.
• Negotiated private secondary. A founder or early employee sells directly to a single buyer (a growth fund, a family office, or another existing investor) at a negotiated price. The company typically still has to consent and waive its Right of First Refusal.
• SPV (special purpose vehicle) purchase. A buyer aggregates a pool of capital into a single-purpose LLC, which then buys shares from one or more sellers. From the seller's tax perspective, this is identical to a negotiated secondary. The SPV structure mostly matters to the buy side.
• Forward contract or structured liquidity. The founder takes a non-recourse advance against future stock value, sometimes through products like ESO Fund or Equitybee-style structures. These are not always treated as sales for tax purposes, but they often are under the constructive sale rules of IRC §1259. Tread carefully.

The QSBS Preservation Problem

Here is the asymmetry that matters most: QSBS treatment dies on the buy side of a secondary, not the sell side.

The original-issuance test under §1202(c)(1)(B) requires that the stock be acquired "at its original issue (directly or through an underwriter) from such corporation." The secondary buyer is purchasing from you, the shareholder, not from the company. So the shares lose QSBS status in the buyer's hands. The buyer will pay ordinary long-term capital gains rates at their eventual exit, with no §1202 exclusion available.

This often surprises growth investors who specialize in secondaries. It also means founders generally get a slight price premium on QSBS stock because the buyer cannot transfer the benefit. The premium is real but modest, usually 5 to 15% above what a non-QSBS comparable would clear.

For the selling founder, the QSBS treatment on the shares sold survives if you met the holding period. Your shares were acquired at original issuance (you bought them from the company at incorporation or on exercise of a founder grant), you held them for the required five years under prior law (pre-OBBBA) or three years for partial exclusion under the post-July 2025 tiered system, and you sold them to a third party. The §1202 exclusion applies to your gain, up to the greater of $10 million or 10x basis per issuer for pre-July 5, 2025 stock; the $15M cap and tiered holding period under the One Big Beautiful Bill Act (OBBBA, Public Law 119-21, signed July 4, 2025) apply to QSBS issued after that date.

The shares you did not sell continue to be QSBS in your hands with their original holding period. A partial secondary does not contaminate the rest of your position.

The Five-Year Clock and the §1045 Rollover

For QSBS issued before July 5, 2025, you get zero federal exclusion if you sell before the five-year mark. For QSBS issued after that date, the OBBBA tiered system gives you 50% at year three, 75% at year four, and 100% at year five. If a tender offer hits at year four on pre-OBBBA shares, you face a hard choice: sell and pay the full long-term capital gains rate (20% federal plus 3.8% NIIT for high earners), or pass and hope another liquidity window opens after year five.

There is a third option that founders often overlook: the §1045 rollover. If you sell QSBS that you held for at least six months but less than the five-year threshold, you can roll the proceeds into replacement QSBS within 60 days and defer the entire gain. Your holding period in the original stock tacks onto the replacement stock, so the rollover preserves your path to eventual exclusion on the new shares.

The replacement stock has to qualify as QSBS at the time of acquisition: domestic C-corp, $75 million or less in aggregate gross assets, active trade or business, original issuance. In practice this usually means investing in another early-stage startup, often through a fund structured to satisfy the §1045 requirements at the LP level. Several venture funds market themselves as QSBS-rollover-compatible.

If you only roll part of the proceeds, you defer only that part. The remainder is taxable in the year of sale. Founders who want to extract some real cash for personal use and roll the rest into a new investment can do that, and the math usually works out cleanly.

Mechanics by Deal Type

Company tender offer

From a tax standpoint, a tender offer is just a structured secondary sale. You sell shares to the participating investor, you receive cash, you have a capital gain. If you held the shares more than one year (almost always true for a founder), the gain is long-term. If you met the QSBS holding period, the §1202 exclusion applies up to the per-issuer cap.

One subtle wrinkle: if the company itself buys back stock in the same window as the tender, the §1202 redemption rules can be triggered. Significant redemptions from related parties within a two-year window of any QSBS issuance can disqualify that issuance. Most tender offers are structured as direct investor purchases (not company buybacks) precisely to avoid this trap, but always read the deal docs.

Negotiated private secondary

Tax treatment is identical to a tender offer: long-term capital gain, QSBS exclusion if eligible. The non-tax friction is heavier: you need company consent, a ROFR waiver, and usually a co-sale waiver from preferred holders. Your stock purchase agreement and the company's bylaws will spell out the consent path. Skip a required consent and the company can refuse to update the cap table, which means the buyer paid for stock the company will not recognize.

SPV purchase

If you sell to an SPV, your tax position is identical to selling to any other buyer: long-term capital gain, QSBS applies if eligible. The SPV itself is usually a partnership or single-member LLC, so it passes the buyer-side QSBS loss through to its investors. None of that affects you as the seller.

Forward contracts and structured advances

Be careful here. If the economic substance of the deal transfers downside risk to the counterparty (a true non-recourse advance with no upside cap), it might be treated as a financing rather than a sale. If there is any upside cap or settlement feature, §1259 constructive sale rules can convert it into a current-year taxable sale at fair market value. The IRS has been aggressive on this. Get a written opinion before signing.

Lockup, ROFR, and Co-Sale: The Non-Tax Gates

Even when the tax math says "go," several contractual provisions can block the sale:

• Lockup. Most founder stock is subject to a lockup either by the company's bylaws or by a side letter with the lead investor. Lockups commonly prohibit any transfer outside a company-approved liquidity window. They survive financings and often persist until IPO or sale.
• Right of First Refusal (ROFR). The company (and sometimes preferred investors) typically has the first right to match any third-party offer. You generally must notify the company in writing, attach the term sheet, and wait out the ROFR period (often 30 to 60 days) before closing.
• Co-sale (tag-along) rights. Some shareholders have the right to participate in your sale pro rata. If they exercise, you sell fewer shares than you planned at the same price.
• Board approval. Some bylaws require explicit board approval for any founder secondary above a threshold. This is common and usually granted, but plan for the timing.

None of these are tax issues. All of them can kill a deal that was tax-favorable. Read your equity documents before negotiating.

Worked Example: $10M Tender at the 5-Year Mark

Sarah founded a Bay Area SaaS C-corp in June 2021. At incorporation she received 5,000,000 shares of common stock at $0.0001 per share, for a total basis of $500. The shares qualified as QSBS at issuance because the company's gross assets were under $50 million (this was pre-OBBBA, so the old $50M threshold applies).

In June 2026, exactly five years later, the company runs a tender offer alongside a Series D round. The lead investor is buying common stock at $20 per share. Sarah is eligible to sell up to 500,000 shares (10% of her position). She elects to sell all 500,000.

The numbers:

• Proceeds: 500,000 shares × $20 = $10,000,000
• Basis: 500,000 × $0.0001 = $50
• Long-term capital gain: $9,999,950
• QSBS exclusion cap (pre-OBBBA): greater of $10M or 10x basis = $10M
• Federal taxable gain after §1202 exclusion: $0
• Federal tax owed: $0

California, however, does not conform to §1202 (the in-state-only exclusion was struck down in Cutler v. Franchise Tax Board and the state repealed it altogether). California treats the entire gain as ordinary long-term capital gain at the top bracket. For Sarah at the 13.3% top rate plus the 1.1% mental health surcharge on income above $1M (effective 14.4%):

• California taxable gain: $9,999,950
• California tax owed (approx 14.4% blended on income above $1M MHSA threshold): ~$1,440,000

Net: Sarah keeps about $8.56M of her $10M tender proceeds. The federal QSBS exclusion saved her roughly $2.38M (20% federal capital gains + 3.8% NIIT on the full $9.99M), but the California check is large enough that planning for residency change, non-grantor trust structuring in a no-tax state, or simply pricing the tax in matters significantly. See our deeper coverage at California equity tax planning and pre-IPO tax strategy.

What Goes Wrong Without a CPA

The most common founder secondary mistake we see at intake: a year-four sale on pre-OBBBA stock with no §1045 rollover analysis. The cost ranges from $400,000 on a $2M tender to $2,500,000 on a $10M tender, all of it federal QSBS exclusion the founder gave up by selling 11 months early. Founders who try to model the math in a spreadsheet routinely miss the California non-conformity ($1M+ on a $9.99M gain), the 83(b) verification step (a missed 83(b) reclassifies the gain as ordinary income at 37%), and the §1202(c)(2) redemption rule that can disqualify QSBS if the company buys back stock within a two-year window. DIY analysis handles the federal exclusion math. It does not flag the §1045 rollover, the company-tender-vs-direct-buyback distinction, or the non-grantor-trust stacking play. Those are the items where engagement pays for itself many times over.

Section 83(b) and Pre-Vest Secondary Sales

Most founder stock is subject to a vesting schedule, usually four years with a one-year cliff. The founder typically files an 83(b) election within 30 days of the original grant, which treats all 5M shares as received and taxed (at the de minimis FMV at grant) immediately, rather than as each tranche vests.

If the 83(b) was filed and is valid, the secondary sale of unvested shares is straightforward: the shares are treated as yours since grant, your holding period began at grant, and the sale is a capital transaction at sale price minus basis. QSBS holding period runs from grant.

If the 83(b) was not filed, you have a problem. Unvested shares are not yet "received" for tax purposes under IRC §83. A sale of unvested shares before vesting can be recharacterized as ordinary compensation income equal to the sale proceeds minus the strike price (which is zero for typical founder common), taxed at your marginal rate (37% federal plus FICA plus state). The QSBS exclusion does not apply to ordinary income. This is a several-million-dollar mistake on a meaningful secondary.

Practical rule: confirm your 83(b) was filed and the IRS has a receipt before agreeing to any pre-vest secondary. If you are not sure, get a copy of the certified-mail return receipt from your records, or pull your tax return for the grant year and confirm the election was attached.

Documentation Your CPA Will Want

For any secondary sale, save and forward to your accountant:

• Original stock purchase agreement (or restricted stock purchase agreement) at incorporation, showing basis and grant date
• Your filed §83(b) election with certified mail receipt
• The company's QSBS representation letter for your shares (request one annually if not provided)
• The most recent 409A valuation, especially if it falls near the sale price
• The tender offer document, ROFR notice, or stock purchase agreement for the secondary
• Closing statement showing gross proceeds, any transfer taxes, and net wire amount
• Documentation of company gross assets at the time of original issuance (for §1202 substantiation)
• If using §1045 rollover: the replacement stock purchase agreement and a written election attached to your return

None of this is exotic, but pulling it together in the week before April 15 is painful. Build the file as the deal closes, not seven months later.

When to Bring SVT In

The decisions that matter most happen before the term sheet is signed. Whether to participate in a tender at year four versus waiting for year five. Whether to roll proceeds into a replacement QSBS or take cash. How much to sell to balance California tax against personal liquidity needs. Whether to gift shares to a non-grantor trust in advance of the sale to stack the §1202 exclusion. All of these are reversible only with significant friction once the deal closes.

We help founders model the math, coordinate with company counsel on the consent path, and document the QSBS substantiation so the eventual tax return is defensible. Our equity compensation practice runs this analysis as flat-fee engagements rather than hourly billable.

Book a consultation if you have a tender offer on the horizon or a buyer at the door. The right time to start is when the conversation begins, not when the wire is scheduled.